BRIEF published on 06/06/2024 at 13:05, 1 year 5 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 1 year 5 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 1 year 6 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 1 year 6 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 1 year 6 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 1 year 6 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 1 year 6 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 1 year 6 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 1 year 7 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 1 year 7 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 12/05/2025 at 02:35, 8 hours 48 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 23 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 18 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 23 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 11:08, 14 minutes ago Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 53 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 8 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 43 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 08:45, 2 hours 38 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 38 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 41 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 8 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 17 hours 23 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
